A cost-effectiveness analysis of sinecatechins in the treatment of external genital warts

Figures & data

Table 1. Initial clearance and recurrence of baseline external genital warts with sinecatechins (Intention to treat results).

Clearance	Intention-to-treat (ITT) (%)	Standard deviation (%)
Complete clearance of baseline warts	55.4 (n=220)	2.49
Recurrence of baseline warts	6.4 (n=14)	1.65

Source: Veregen NDA 2005; combined trials CT1017 and CT1018 (n=397)

Table 2. Summary of model inputs for cost-effectiveness evaluation.

Cost-effectiveness model inputs	Input values
Initial clearance of baseline warts
At 8 weeks At 16 weeks Recurrence	Sinecatechins 20.9%/imiquimod 22.2%Sinecatechins 55.4%/imiquimod 52.3%Sinecatechins 6.4%Imiquimod 22.3%
Drug unit costs and average utilization
Sinecatechins Imiquimod	2.29 × 15 g tubes @ $275.86 (AWP Dec 2008)1.25 × 24-packet boxes @ $624.90 (AWP Jun 2009)
Drug costs (course of treatment)
Sinecatechins Imiquimod	$631.72$781.13
Physician visits
CPT99202 CPT99213 CPT99214	$63.48$61.31$92.33
Procedure costs (males)
CPT54056 CPT54065 Average/patient treated	$125.87$205.22$165.54
Procedure costs (females)
CPT56501 CPT56515 Average/patient treated	$122.99$209.91$166.45

Table 3. Modeled cost-effectiveness outcomes: sinecatechins and imiquimod.

Outcome	Sinecatechins	Imiquimod
Sustained clearance	51.9%	40.6%
Average cost of first-line therapy	$774	$930
Cost per successful outcome	$1,492	$2,289
Cost of first- and initial second-line therapy	$943	$1,138
First-line average cost advantage with sinecatechins	$156
First- and second-line cost advantage with sinecatechins	$196